- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Express Scripts Adds COPD, Asthma Treatments to National Formulary
The formulary covers over 22 million US lives.
Several treatments for chronic obstructive pulmonary disease (COPD) and asthma from Boehringer Ingelheim were recently added to the Express Scripts (ESI) Commercial National Preferred Formulary.
The formulary covers over 22 million US lives. The changes took effect May 15, 2020.
The COPD treatments are:
- Tiotropium bromide (Spiriva Respimat) inhalation spray 2.5 mcg
- Tiotropium bromide (Spiriva Handihaler) inhalation powder
- Tiotropium bromide and olodaterol (Stiolto Respimat) inhalation spray
In addition, tiotropium bromide (Spiriva Respimat) inhalation spray 1.25 mcg was added for asthma.
“This important decision will provide people living with asthma and COPD additional options to consider when making treatment decisions with their healthcare providers,” said Chris Marsh, senior vice president, market access at Boehringer Ingelheim, said in a statement. “Not only does this decision reinforce the value and impact of our respiratory portfolio, but it serves as another example of our commitment to ensure our medicines are available to our patients who need them.”
According to the CDC, COPD is the third-leading cause of death in the United States. Almost 15.7 million Americans reported that they have been diagnosed with COPD, but the CDC has said that actual numbers may be higher, because more than 50% of adults with low pulmonary function were not aware that they had COPD.
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Study: 1 in 6 US Patients With COPD Suffers From Cost-Related Medication Nonadherence
April 3rd 2024Medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) is associated with increasing COPD symptoms, hospitalizations, morbidity, mortality, and health care expenditures.
Read More
Dose-Escalation, Low-Dose Regimens May Improve Roflumilast Treatment Adherence in Patients With COPD
March 24th 2024This study suggests that dose-escalation or low-dose regimens for roflumilast treatment in patients with chronic obstructive pulmonary disease (COPD) may improve adherence.
Read More
